Overview

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

Status:
Completed

Trial end date:
2016-04-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

AZD7624